版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1、Overview of Atherothrombotic Therapy: Secondary Prevention2002 ACC/AHA UA/NSTEMI* Guideline Update: Risk Factor ModificationClass ISmoking cessation Achieving optimal weight Daily exerciseAHA diet BP control to 130 mg/dLLipid-lowering agent if LDL-C after diet is 100 mg/dLA fibrate or niacin if HDL-
2、C 140 mm Hg is a much more important CVD risk factor than diastolic DBP.The risk of CVD, beginning at 115/75 mm Hg, doubles with each increment of 20/10 mm Hg.Individuals with a SBP of 120 to 139 mm Hg or a DBP of 80 to 89 mm Hg should be considered prehypertensive and require health-promoting lifes
3、tyle modifications to prevent CVD.SBP, systolic blood pressure; CVD, cardiovascular disease; DBP, diabolic blood pressure.Chobanian AV, et al. JAMA. 2003;289:2560-2572.Thiazide-type diuretics should be used in drug treatment for most patients with uncomplicated hypertension, either alone or combined
4、 with drugs from other classesMost patients with hypertension will require 2 or more antihypertensive medications to achieve goal BP (140/90 mm Hg, or 20/10 mm Hg above goal BP, consideration should be given to initiating therapy with 2 agents, 1 of which usually should be a thiazide-type diureticTh
5、e most effective therapy prescribed by the most careful clinician will control hypertension only if patients are motivatedThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureSBP, systolic blood pressure; CVD, cardiovascular dis
6、ease; DBP, diabolic blood pressure.Chobanian AV, et al. JAMA. 2003;289:2560-2572.Classification and Management of Adult Blood PressureBPClassificationSBP, mm HgDBP, mm HgLifestyleModificationNormal12080EncouragePrehypertension120-13980-89YesStage 1hypertension149-15990-99YesStage 2hypertension160100
7、YesChobanian A V, et al. JAMA. 2003;289:2560-2572. (with permission)Algorithm for Treatment of HypertensionChobanian AV, et al. JAMA. 2003;289:2560-2572. (with permission)Lifestyle ModificationsNot at Goal BP(140/90 mm HG or 130 mg/dL Lipid-lowering agents if LDL-C level after diet is 100 mg/dL1. AC
8、E inhibitors for patients with CHF, LV dysfunction (EF 0.40), hypertension, or diabetesACC, American College of Cardiology; AHA, American Heart Association; UA, unstable angina; NSTEMI, nonST-segment elevation myocardial infarction; ACS, acute coronary syndrome; LDL-C, low-density lipoprotein choles
9、terol; ACE, angiotensin-converting enzyme; CHF, coronary heart failure; LV, left-ventricular; EF, ejection-fraction.Braunwald E, et al. J Am Cardiol.2000;36:970-1062.Category % ORAcute MIAcute stroke Prior MI Prior stroke/TIAOther high riskCoronary artery disease(unstable angina, heart failure)Perip
10、heral arterial disease(intermittent claudication) 22 2 %High risk of embolism (atrial fibrillation)Other (diabetes mellitus)All trials1.00.50.01.52.0Control BetterAntiplatelet BetterAntithrombotic Trialists Collaboration (ATC): Efficacy of Antiplatelet Therapy on Vascular Events* Vascular events = M
11、I, stroke, or vascular death.OR, odds reduction; MI, myocardial infarction; TIA, tranient ischemic attack.Antithrombotic Trialists Collaboration. BMJ. 2002;324:71-86. (with permission)Aspirin Alone BetterCombined With AspirinAntithrombotic Trialists Collaboration1Dipyridamole6NSTiclopidine 20NSIV GP
12、 IIb/IIIa-Inhibitor 19P .0001Subtotal15P .0001OR Comparison* (%) P ValueCURE2Clopidogrel20P =.000091.00.50.01.52.0Effects of Various Antiplatelet Agents Combined With Aspirin vs Aspirin Alone* In combination with aspirin vs aspirin alone. CURE, Clopidogrel in Unstable angina to prevent Recurrent Eve
13、nts. 1 Antithrombotic Trialists Collaboration. BMJ. 2002;324:71-86. 2The CURE Trial Investigators. N Engl J Med. 2001;342:494-502. ATC: Efficacy of Aspirin at Various Doses in Reducing Vascular Events* in High-Risk Patients* Vascular events included nonfatal MI, nonfatal stroke, and death from vascu
14、lar causes. Treatment effect P.0001. Adapted with permission from the BMJ Publishing Group. ATC, Antithrombotic Trialists Collaboration, MI, myocardial infarctionAdapted from Antithrombotic Trialists Collaboration. BMJ. 2002;324:71-86.0.51.01.52.0500-1500 mg 34 19160-325 mg 19 2675-150 mg 12 3275 mg
15、 3 13Any aspirin 65 23Antiplatelet BetterAntiplatelet WorseAspirin Dose No. of Trials OR (%)Odds Ratio0Aspirin Resistance and the Risk ofCardiovacular Events in High Risk Patients5529 pts from HOPE study with baseline urine samplesCase (n=488)Pts with CV events after randomizationControls (n=488)Pts
16、 without CV events after randomizationUrinary 11-dehydro Thromboxane B2(ng/mmol creatinine)00.511.5233.81.01.31.41.8MI, stroke or CV death (P=.01)Odd RatioHypothesis: Incomplete inhibition of thromboxane B2 increases risk of cardiovascular eventAdapted from Eikelboom JW, et al. Circulation. 2002;105
17、:1650-1655.Cholesterol Reduction Reduces Incidence of Vascular Events in Diabetes0510152025300123456Log rank P.0001Simvastatin-allocatedPlacebo-allocatedFollow-up (years)Major vascular events (%)Heart Protection Study Collaborative Group. LANCET. 2003;361:2005-2016. (with permission)Cholesterol Redu
18、ction in Diabetes With or Without Arterial Disease010203040Heart Protection Study Collaborative Group. Lancet. 2003;361:2005-2016. (with permission)DiabetesOcclusive Arterial Both ArterialAloneDisease AloneDisease andDiabetes9%13%20%25%31%36%Risk reduction (SE):Proportional32.9% (9.1)24.5% (3.1)18.4
19、% (5.7)Absolute/100044 (12)62 (8)66 (21)P-Value.00032X upper limit of normal 3 (1%) 2 (1%)2 (1%)2 (1%)3 (1%)ALP 1-5X upper limit of normal 10 (2%) 10 (3%)12 (4%)11 (4%)19 (6%)Wallentin L, et al. Lancet. 2003;362:789-797. (with permission)van Es, et al. Lancet. 2002;360:109-113. (with permission)ASPE
20、CT IIWARIS IIWarfarin With or Without Aspirin Post ACS/MIDeath,MI,CVA Hurlen M, et al. NEJM. 2002;347:969-974. (with permission)Cumulative Treatment Failure (%)Logrank test: P=.03CoumadinAspirinCombinationPatients at riskComb.AspirinCoumadin3253252331881591055433628223318615910056332293243197161102600.140.120.100.080.060.040.020Event-free SurvivalFollow up
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2026国家管网集团广西公司秋季高校毕业生招聘考试参考题库(浓缩500题)附参考答案详解(基础题)
- 2026秋季国家管网集团湖南公司高校毕业生招聘4人考试备考试题(浓缩500题)带答案详解(综合题)
- 2026秋季国家管网集团油气调控中心高校毕业生招聘14人考试参考试题(浓缩500题)带答案详解(新)
- 2026秋季国家管网集团储运技术发展有限公司高校毕业生校园招聘笔试参考题库(浓缩500题)及答案详解(历年真题)
- 2026国家管网集团高校毕业生招聘考试参考试题(浓缩500题)含答案详解
- 2026国家管网集团甘肃公司秋季高校毕业生招聘25人考试参考题库(浓缩500题)带答案详解(培优a卷)
- 2025国网浙江省电力公司高校毕业生提前批招聘笔试模拟试题浓缩500题及参考答案详解一套
- 2026年大兴安岭地区农村信用社联合社秋季校园招聘笔试备考题库(浓缩500题)及答案详解(真题汇编)
- 2026国网四川省高校毕业生提前批招聘(约450人)笔试模拟试题浓缩500题附答案详解(研优卷)
- 2026国网湖北省电力公司高校毕业生提前批招聘笔试模拟试题浓缩500题附答案详解(突破训练)
- BIM在施工成本控制中的作用分析
- 国家开放大学《监督学》形考任务( 1-4)试题和答案解析
- 冲压车间考勤管理制度
- 2025年上海市公务员录用考试《行测》A类真题及答案解析(回忆版)
- 房地产经纪人业务操作考试真题及答案(2025年新版)
- 现场质量问题处理流程培训
- 《局解腹部》课件
- 医院感染管理规范
- 农业技术推广2024年试题及答案
- 血液入库制度与流程
- 《速写基础》全套教学课件
评论
0/150
提交评论